TRVI Quote, Financials, Valuation and Earnings

iBio has a net margin of -- compared to Trevi Therapeutics's net margin of -4444.57%. Trevi Therapeutics's return on equity of -- beat iBio's return on equity of -148.3%.

Trevi Therapeutics has a consensus price target of $9.43, signalling upside risk potential of 145.31%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 49.05%. Given that Trevi Therapeutics has higher upside potential than iBio, analysts believe Trevi Therapeutics is more attractive than iBio.

Trevi Therapeutics has a beta of 0.958, which suggesting that the stock is 4.172% less volatile than S&P 500. In comparison iBio has a beta of -3.237, suggesting its less volatile than the S&P 500 by 423.713%.

Trevi Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trevi Therapeutics pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.

Trevi Therapeutics quarterly revenues are --, which are smaller than iBio quarterly revenues of $175K. Trevi Therapeutics's net income of -$13.2M is lower than iBio's net income of -$4M. Notably, Trevi Therapeutics's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trevi Therapeutics is -- versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.

Keros Therapeutics has a net margin of -- compared to Trevi Therapeutics's net margin of -13648.45%. Trevi Therapeutics's return on equity of -- beat Keros Therapeutics's return on equity of -44.6%.

Trevi Therapeutics has a consensus price target of $9.43, signalling upside risk potential of 145.31%. On the other hand Keros Therapeutics has an analysts' consensus of $43.55 which suggests that it could grow by 160.6%. Given that Keros Therapeutics has higher upside potential than Trevi Therapeutics, analysts believe Keros Therapeutics is more attractive than Trevi Therapeutics.

Trevi Therapeutics has a beta of 0.958, which suggesting that the stock is 4.172% less volatile than S&P 500. In comparison Keros Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Trevi Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Keros Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trevi Therapeutics pays -- of its earnings as a dividend. Keros Therapeutics pays out -- of its earnings as a dividend.

Trevi Therapeutics quarterly revenues are --, which are smaller than Keros Therapeutics quarterly revenues of $388K. Trevi Therapeutics's net income of -$13.2M is higher than Keros Therapeutics's net income of -$53M. Notably, Trevi Therapeutics's price-to-earnings ratio is -- while Keros Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trevi Therapeutics is -- versus 895.26x for Keros Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Trevi Therapeutics's net margin of -49.65%. Trevi Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Trevi Therapeutics has a consensus price target of $9.43, signalling upside risk potential of 145.31%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 589.94%. Given that NovaBay Pharmaceuticals has higher upside potential than Trevi Therapeutics, analysts believe NovaBay Pharmaceuticals is more attractive than Trevi Therapeutics.

Trevi Therapeutics has a beta of 0.958, which suggesting that the stock is 4.172% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Trevi Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trevi Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Trevi Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Trevi Therapeutics's net income of -$13.2M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Trevi Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trevi Therapeutics is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Trevi Therapeutics's net margin of -2357.27%. Trevi Therapeutics's return on equity of -- beat Palatin Technologies's return on equity of --.

Trevi Therapeutics has a consensus price target of $9.43, signalling upside risk potential of 145.31%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1617.17%. Given that Palatin Technologies has higher upside potential than Trevi Therapeutics, analysts believe Palatin Technologies is more attractive than Trevi Therapeutics.

Trevi Therapeutics has a beta of 0.958, which suggesting that the stock is 4.172% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Trevi Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trevi Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Trevi Therapeutics quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Trevi Therapeutics's net income of -$13.2M is lower than Palatin Technologies's net income of -$7.8M. Notably, Trevi Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trevi Therapeutics is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.